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Abstract
Background: Germline mutations in BRCA1/2 greatly elevate risks of breast and ovarian cancers,
but the role of these genes in tumourigenesis of other cancer types is still being investigated.
Objective: We report on an investigation of BRCA1/2 mutations and their loss of heterozygosity
(LOH) in a patient with a strong family history of breast cancer who was diagnosed with
consecutive primary cervical, ovarian and lung carcinomas.
Methods and results: BRCA1/2 mutation screening of the proband revealed a common familial
breast- and ovarian cancer-associated germline BRCA2 mutation (3034del4bp). We then performed
LOH analysis for BRCA2 in lung adenocarcinoma tissue of the patient. Using the laser-capture
microdissection (LCM) technique, we obtained pure populations of neoplastic cells from which
DNA could be extracted. Mutation analysis by denaturing high-performance liquid chromatography
(DHPLC) and direct sequencing revealed loss of the mutant allele in the adenocarcinoma tumour
tissue.
Conclusion: To our knowledge, this is the first report of investigation for LOH for BRCA2 in
primary lung adenocarcinoma tissue of a patient with multiple primary tumours related to a familial
germline BRCA2 mutation. Interestingly, it was the mutant, not the wild-type, allele which was lost
in the lung adenocarcinoma tissue.
Introduction
Germline mutations in the breast cancer susceptibility
genes BRCA1 and BRCA2 are strongly associated with an
elevated risk of breast and ovarian cancers [1]. Mutation
carriers also have a statistically increased risk for several
other cancers; i.e. pancreatic cancer and carcinoma of the
uterine body and cervix for BRCA1 [2], and prostate, pan-
creatic, biliary, and gastric cancers, and malignant
melanoma for BRCA2 [3]. LOH at the BRCA2 locus has
been observed in several tumours other than breast and
ovary, i.e. tumours of the prostate, cervix, colon and ureter
in patients with germline mutations in that gene [4]. LOH
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analysis of tumour tissues in multiple-cancer patients who
harbour mutations in cancer-related genes is one means
for investigating the contribution of these genes to the
oncogenesis of these cancers. Using this strategy, we per-
formed  BRCA1/2 mutational analysis of germline cells
and LOH analysis of lung adenocarcinoma tumour cells
to investigate the role of BRCA1/2 tumourigenesis in lung
adenocarcinoma in this patient with primary cervical,
ovarian and lung cancers and a strong family history of
breast cancer.
Case Report
A 46-year-old woman presented to the Department of
Clinical Genetics, University of Heidelberg with multiple
primary carcinomas and a family history of breast cancer.
Her mother was diagnosed with bilateral breast cancer at
the age of 29 years. The patient's sister was found to have
breast cancer at age 49 years. Additionally, two maternal
aunts had postmenopausal breast cancer (Fig. 1). Our
patient had three primary tumours: cervical carcinoma at
age 23, right ovarian carcinoma at age 33 and primary
lung carcinoma at age 45 years. None of the tumours were
treated with chemotherapy. The patient smoked one pack
of cigarettes per day for ten years prior to her lung cancer
diagnosis.
Methods and Results
Screening for BRCA1 and BRCA2 germline mutations
We obtained prior written informed consent from our
patient using protocols approved by the Ethics Commit-
tee of the Medical Faculty at the University of Heidelberg,
Germany. Genomic DNA was isolated from blood using
standard procedures. To amplify exon and exon-intron
boundaries, we used primer pairs and polymerase chain
reaction (PCR) protocols as previously published [5].
Mutational screening for BRCA1 and BRCA2 mutations
was carried out by prescreening with denaturing high-per-
formance liquid chromatography (DHPLC) analysis and
direct sequencing as described elsewhere [5]. DHPLC
analysis of amplified genomic DNA of our patient showed
a distinctive elution profile in exon 11 of BRCA2 (Fig.
2A,2B,2C), and dye terminator sequencing identified the
exact sequence alteration. We detected the common breast
cancer-associated frameshift mutation 3034del4bp (Fig.
Pedigree of the patient's family showing strong family history of breast cancer (BC) Figure 1
Pedigree of the patient's family showing strong family history of breast cancer (BC). Filled symbols (black) represent cancer 
cases. Ages of disease onset are shown in years. The index patient is indicated with an arrow.
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3A), which causes premature protein termination at
codon 958.
Loss of heterozygosity (LOH) analysis of tumour tissue
LOH analysis was performed in the bronchial adenocarci-
noma tissue only, as tissue samples of the other primary
tumours were not available. Sections (5 µm) of the paraf-
fin-embedded lung carcinoma sample were stained by
hematoxylin and eosin (H&E) and periodic acid Schiff
(PAS) using standard protocols. Distinct neoplastic cells
(approx. 500) were collected by laser-mediated microdis-
section and subsequent laser pressure catapulting method
as previously described [6]. In brief, three 5 µm thin sec-
tions including tumourous and nontumourous lung tis-
sue were placed in xylene and deparaffinated. The slide
was placed on the stage of a laser-guided zoom stereo
microscope and the tumour tissue was excised by laser
microdissection. A plane of cleavage could easily be devel-
oped between cells for analysis and those to be left
behind. As the periphery of the target area became ele-
vated, the laser tip could segment the contralateral piece,
until the whole area was undermined and detached. Sin-
gle fragments were aspirated into a micropipette tip and
transferred to a microcentrifuge tube. The remaining
tissue was stained with H&E to test the appropriateness of
the microdissection. We used a commercially-available
DHPLC elution profiles of 463 base pair PCR fragments of BRCA2 exon 11 Figure 2
DHPLC elution profiles of 463 base pair PCR fragments of BRCA2 exon 11. A: Heteroduplex profile with two peaks from con-
trol DNA that was found to be heterozygous for the common exon 11 BRCA2 mutation 3034del4bp. B: Homoduplex profile 
(DHPLC) in amplified wild-type DNA. C: DHPLC analysis of amplified genomic DNA of our patient showing a heteroduplex 
profile similar to the profile of the mutant control DNA sample. D: DHPLC elution profile of amplified lung tumour DNA 
showing only one peak indicating LOH, either of the wild-type or the mutant allele.
A Control DNA (BRCA2 3034del4bp) B Control DNA (wildtype)
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UV-Laser Microbeam System (Robot-MicroBeam,
P.A.L.M. GmbH, Bernried, Germany). The dissected cells
were digested in PCR buffer with proteinase K (2 µl of 20
mg/ml stock solution). Samples were incubated with
shaking at 56°C for 12 hr followed by inactivation of pro-
teinase K at 96°C for 10 min. Two µl of this solution con-
taining tumour DNA was amplified using PCR and
analysed by DHPLC as described above. Elution profiles
of wild-type control DNA and tumour tissue DNA showed
similar single peaks (Fig. 2B,2D), indicating homodu-
plices. Sequence analysis of the same fragment revealed
loss of the mutant allele but not of the wild-type allele in
the tumour cells (Fig. 3).
Discussion
Knudson's two-hit hypothesis for the genesis of hereditary
cancer predicts that cancer may develop when the wild-
type allele of a tumour suppressor gene is lost in an indi-
vidual with a germline mutation in that gene [7]. Our
female patient had multiple tumours and strong family
history of breast cancer. Sequence analysis of germline
cells revealed a frameshift mutation in exon 11 of BRCA2.
This mutation, 3034del4bp, is listed in the Breast Cancer
Information Core (BIC) 18 times and is known to be asso-
ciated with familial breast and ovarian cancer [8]. BRCA
genes conform to the classic paradigm for tumour sup-
pressor genes in that loss of the wild-type allele can be
found in tumour cells isolated from predisposed individ-
Results of direct sequencing-amplified genomic (A) and lung tumour DNA (B) of our patient Figure 3
Results of direct sequencing-amplified genomic (A) and lung tumour DNA (B) of our patient. A: Direct sequencing reveals het-
erozygosity beginning from position 3034 of the BRCA2 gene (C/T, arrow), that was shown to be a deletion of 4 base pairs 
(AAAC) leading to frame shift and premature termination of translation in position 958 of BRCA2 protein. B: "Homozygosity" 
for the wild-type allele around position 3034 of BRCA2, most likely as a result of chromosomal deletion of the mutant allele, 
was found by sequencing analysis (arrow).
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uals [9]. Therefore, we performed LOH analysis on our
patient's lung adenocarcinoma tissue to investigate the
involvement of BRCA2  in the genesis of this tumour.
Unfortunately, neither cervical nor ovarian cancer tumour
tissues were available for analysis. Subsequent DNA anal-
ysis by DHPLC and direct sequencing in the lung adeno-
carcinoma revealed loss of the mutant, but not of the
wild-type allele. The loss of an abnormal cancer-associ-
ated germline BRCA2 mutation rather than a normal pro-
tective allele would intuitively seem to argue against a
causative role of the germline BRCA2 mutation in the lung
adenocarcinoma in this patient. BRCA2 is comprised of
27 exons encoding 3,418 amino acids. Our patient carries
a germline mutation in exon 11 of the BRCA2 gene lead-
ing to a termination of the protein sequence after 958
aminoacids. We assume that the protein encoded by the
mutant allele is strongly reduced in its function, and loss
of an essentially nonfunctional protein product, leaving
only the normal tumour suppressor gene product should
not lead to tumour formation. It remains the possibility
that the wild-type allele of BRCA2 in the tumour tissue
was knocked out by a deleterious point mutation that
could not be identified with the here described methods.
To test this more unlikely hypothesis, an extensive muta-
tion screen of the entire coding region of BRCA2 in the
lung tumour tissue would have been necessary. Alterna-
tively, deletions of other genes located near the BRCA2
locus of the deleted mutant allele might also participate in
lung adenocarcinoma oncogenesis. Investigation of the
extensiveness of the chromosomal deletion in the neo-
plastic cells might be helpful in suggesting mechanisms of
disease in this case. Certainly, other mechanisms of
tumourigenesis for the lung adenocarcinoma in this
patient unrelated to BRCA2 mutation must be considered,
especially in light of a history of cigarette smoking.
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